small molecule

TUKYSA

TUCATINIB

Loss of exclusivityApril 2038latest FDA-listed patent expiry

CompanySeagen →See this company's full patent-cliff portfolio

Drug detail

Brand name	TUKYSA
Active ingredient	TUCATINIB
Strength	150MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	April 2020
Marketing status	RX

Listed patents

Patent	Expires	Type
11207324	April 2038	use U-3783
11666572	April 2038	use U-3783
12048698	April 2038	use U-3783
8648087	April 2034	substance, product
11504370	March 2033	use U-2788
9457093	October 2032	product
9693989	May 2027	product

Regulatory exclusivity

Code	Expires
ODE-422	January 2030
ODE-309	April 2027
I-906	January 2026

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Seagen